Galapagos NV
GLPG
#4565
Rank
NZ$3.70 B
Marketcap
NZ$56.20
Share price
2.31%
Change (1 day)
18.69%
Change (1 year)

Earnings for Galapagos NV (GLPG)

Earnings in 2025 (TTM): -NZ$0.92 Billion

According to Galapagos NV's latest financial reports the company's current earnings are NZ$0.32 Billion. In 2024 the company made an earning of -NZ$10.04 Million, an increase over its 2023 earnings that were of -NZ$58.26 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Galapagos NV from 2015 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -NZ$0.92 Billion9004.89%
2024 -NZ$10.04 Million-82.77%
2023 -NZ$58.26 Million-85.59%
2022 -NZ$0.41 Billion60.71%
2021 -NZ$0.26 Billion-60.08%
2020 -NZ$0.64 Billion-331.44%
2019 NZ$0.27 B-523.76%
2018 -NZ$64.27 Million-72.34%
2017 -NZ$0.24 Billion-329.59%
2016 NZ$0.10 B-144.3%
2015 -NZ$0.23 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
AstraZeneca
AZN
NZ$22.73 B-2,558.70%๐Ÿ‡ฌ๐Ÿ‡ง UK
Johnson & Johnson
JNJ
NZ$56.26 B-6,184.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$15.80 B-1,809.31%๐Ÿ‡ซ๐Ÿ‡ท France
AbbVie
ABBV
NZ$2.88 B-411.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Fortress Biotech
FBIO
-NZ$92.87 Million-89.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
NZ$14.13 B-1,628.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$3.07 B-432.84%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
GlaxoSmithKline
GSK
NZ$16.19 B-1,851.12%๐Ÿ‡ฌ๐Ÿ‡ง UK
Merck
MRK
NZ$40.10 B-4,437.01%๐Ÿ‡บ๐Ÿ‡ธ USA